Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 12/2017

01.12.2017 | Neuro-oncology (S Nagpal, Section Editor)

A Metabolic Therapy for Malignant Glioma Requires a Clinical Measure

verfasst von: Zachary Corbin, Daniel Spielman, Lawrence Recht

Erschienen in: Current Oncology Reports | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Cancers are “reprogrammed” to use a much higher rate of glycolysis (GLY) relative to oxidative phosphorylation (OXPHOS), even in the presence of adequate amounts of oxygenation. Originally identified by Nobel Laureate Otto Warburg, this hallmark of cancer has recently been termed metabolic reprogramming and represents a way for the cancer tissue to divert carbon skeletons to produce biomass. Understanding the mechanisms that underlie this metabolic shift should lead to better strategies for cancer treatments. Malignant gliomas, cancers that are very resistant to conventional treatments, are highly glycolytic and seem particularly suited to approaches that can subvert this phenotype.
Literatur
1.
Bensinger, S.J. and H.R. Christofk. New aspects of the Warburg effect in cancer cell biology. Sem Cell Develop Biol. 2012.
2.
3.
Turcan S, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479–83.
4.
5.
Hu Y, Wilson GS. A temporary local energy pool coupled to neuronal activity: fluctuations of extracellular lactate levels in rat brain monitored with rapid-response enzyme-based sensor. J Neurochemistry. 1997;69:1484–90.CrossRef
6.
Galeffi F, et al. Lactate uptake contributes to the NAD(P)H biphasic response and tissue oxygen response during synaptic stimulation in area CA1 of rat hippocampal slices. J Neurochemistry. 2007;103:2449–61.CrossRef
7.
Warburg O. The metabolism of tumours. London: Arnold Constable; 1930.
8.
Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J General Physiol. 1927;8:519–30.CrossRef
9.
Ak, P. and A.J. Levine. p53 and NF-kB: different strategies for responding to stress leads to a functional antagonism. FASEB J. 2010.
10.
11.
Gleeson, L.E. and F.J. Sheedy. Metabolic reprogramming & inflammation: fuelling the host response to pathogens. Semin Immunol. 2016.
12.
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–34. A very coherent explanation of the cellular underpinnings of the Warburg effect CrossRefPubMedPubMedCentral
13.
Vander Heiden, M.G., et al. Metabolic pathway alterations that support cell proliferation. Cold Spring Harbor Symposium on Quant Biology. 2012.
14.
Kilburn DG, Lilly MD, Webb FC. The energetics of mammalian cell growth. J Cell Science. 1969;4:645–54.PubMed
15.
Racker E. Why do tumor cells have a high aerobic glycolysis. J Cell Physiol. 1976;89:697–700.CrossRefPubMed
16.
Nathan C, Ding A. SnapShot: reactive oxygen intermediates (ROI). Cell Cycle. 2010;140:951.
17.
Mekhail K, et al. HIF activation by pH-dependent nucleolar sequestration of VHL. Nat Cell Biol. 2004;6:642–7.CrossRefPubMed
18.
Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 2002;277:23111–5.CrossRefPubMed
19.
Draoui N, Feron O. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Disease Models & Mech. 2011;4:727–32.CrossRef
20.
• Sonveaux P, et al. Targeted lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clinical Investigation. 2008;118:3930–42. Describes intercellular relationships wherein rates of GLY to OXPHOS are determined by hypoxia. Offers insight into the underpinnings of metabolic symbiosis
21.
Vegran F, et al. Lactate influx through the endothelial cell monocarboxylate transporter (MCT) supports and NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res. 2011;71:2550–60.CrossRefPubMed
22.
• Fantin VR, St.-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9:425–34. Demonstrates how targeting an isoform of LDH overexpressed by cancer cells can slow growth CrossRefPubMed
23.
Le A, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010;107:2037–42.CrossRefPubMedPubMedCentral
24.
Fischer K, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109:3812–9.CrossRefPubMed
25.
Dietl K, et al. Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes. J Immunology. 2010;184:1200–9.CrossRef
26.
Herling, A., et al. Enzymatic features of the glucose metabolism in tumor cells. FEBS J. 2011.
27.
Marin-Hernandez A, et al. Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an overexpressed but strongly product-inhibited hexokinase. FEBS J. 2006;273:1975–88.CrossRefPubMed
28.
DeBerardinis RJ, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2008;104:19345–50.CrossRef
29.
30.
Wise DR, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105:18782–7.CrossRefPubMedPubMedCentral
31.
32.
Fan Y, Dickman KG, Zong WX. Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem. 2010;285:7324–33.CrossRefPubMed
33.
Figueroa ME, et al. Leukemic IDH1 and IDH2 mutations result in an hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553–67.CrossRefPubMedPubMedCentral
34.
Xu W, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19:17–30.CrossRefPubMedPubMedCentral
35.
Nakajima, E.C. and B. Van Houten. Metabolic symbiosis in cancer: refocusing the Warburg lens. Mol Carcinogen. 2012.
36.
Pavlides S, et al. The reverse Warburg effect. Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009;8:3984–4001.CrossRefPubMed
37.
38.
Coe EL, Strunk RC. The effect of oxamate on glycolysis in intact ascites tumor cells. I. Kinetic evidence for a dual glycolytic system. Biochimica et Biophys Acta. 1970;208:189–202.CrossRef
39.
Stafford P, et al. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjunctive therapy for glioma. Nutrition & Metabolism. 2010;7:74.CrossRef
40.
Mukherjee P, Abate LE, Seyfried TN. Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clinical Cancer Res. 2004;10:5622–9.CrossRef
41.
Seyfried, T.N., et al. Metabolic management of brain cancer. Biochimica et Biophys Acta. 2010.
42.
Zuccoli G, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutrition & Metabolism. 2010;7:33.CrossRef
43.
Rempel A, et al. Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res. 1996;56:2468–71.PubMed
44.
Wolf, A., et al.. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2011: 1–14.
45.
Stein M, et al. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate. 2010;70:1388–94.CrossRefPubMedPubMedCentral
46.
Singh D, et al. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol. 2005;181:507–14.CrossRefPubMed
47.
Prasanna VK, et al. Differential responses to tumor and normal brain to the combined treatment of 2-DG and radiation in glioblastoma. J Cancer Res Ther. 2005;5(suppl 1):44–7.
48.
Boros LG, et al. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res. 1997;57:4242–8.PubMed
49.
Rais B, et al. Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich’s tumor cells through inhibition of the pentose cycle. FEBS Letts. 1999;456:113–8.CrossRef
50.
Libby G, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32:1620–5.CrossRefPubMedPubMedCentral
51.
Anisimov VN, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontology. 2005;40:685–93.CrossRef
52.
53.
Thangaraju M, et al. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem J. 2009;417:379–89.CrossRefPubMed
54.
Thangaraju M, et al. SLCA8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res. 2006;66:11560–4.CrossRefPubMed
55.
Kim DY, et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3:177–85.CrossRefPubMed
56.
Papandreou I, et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen-consumption. Cell Metab. 2006;3:187–97.CrossRefPubMed
57.
Knoechel TR, et al. Regulatory roles of the N-terminal domain based on crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands. Biochemistry. 2006;45:402–15.CrossRefPubMed
58.
Papandreou, I., T. Goliasova, and N.C. Denko. Anti-cancer drugs that target metabolism, is dichloroacetate the new paradigm. Int J Cancer. 2010.
59.
Sun RC, et al. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat. 2010;120:253–60.CrossRefPubMed
60.
Stockwin LH, et al. Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC. Int J Cancer. 2010;127:2510–9.CrossRefPubMed
61.
Michelakis ED, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010;2:31ra34.CrossRefPubMed
62.
Wise DR, et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A. 2011;108:19611–6.CrossRefPubMedPubMedCentral
63.
64.
• Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis. Nat Rev Cancer. 2004;4:891–9. One of the best review articles on the Warburg effect CrossRefPubMed
65.
Xu RH, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005;65:613–21.PubMed
66.
Kaura B, Bagga R, Patel FD. Evaluation of the pyruvate kinase type M2 (Tu M2-PK) as a tumor marker for cervical carcinoma. J Obstet Gynaecol Res. 2004;30:193–6.CrossRefPubMed
67.
68.
Lagerwaard FJ, et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43:795–803.CrossRefPubMed
69.
Koukourakis MI, et al. Serum and tissue LDH levels in patients with breast/gynecological cancer and benign diseases. Gynecol Obstet Investig. 2009;67:162–8.CrossRef
70.
Kurhanewicz J, et al. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation of clinical research. Neoplasia. 2011;13:81–97.CrossRefPubMedPubMedCentral
71.
72.
73.
Nelson SJ, et al. In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J Magn Reson Imaging. 2002;16:464–76.CrossRefPubMed
74.
Gillies RJ, Morse DL. In vivo magnetic resonance spectroscopy in cancer. Ann Rev Biomed Eng. 2005;7:287–326.CrossRef
75.
Andronesi OC, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012;4(116ra4):1–12.
76.
Abragam A, Goldman M. Principles of dynamic nuclear polarization. Rep Prog Phys. 1978;41:395–9.CrossRef
77.
Ardenkjaer-Larsen JH, et al. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A. 2003;100:10158–63.CrossRefPubMedPubMedCentral
78.
Hurd RE, et al. Metabolic imaging in the anesthetized rat brain using hyperpolarized [1-13C] pyruvate and [1-13C] ethyl pyruvate. Magn Reson Med. 2010;63:1137–43.CrossRefPubMedPubMedCentral
79.
80.
Darpolor, M.M., et al.. In vivo MRSI of hyperpolarized [1-(13)C]pyruvate metabolism in rat hepatocellular carcinoma. NMR Biomed. 2010.
81.
Park I, et al. Detection of early response to temozolomide treatment in brain tumors using hyperpolerized 13C MR metabolic imaging. J Magnetic Resonance Imaging. 2011;33:1284–90.CrossRef
82.
Chaumeil, M.M., et al. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. NeuroImage. 2011.
83.
Zierhut ML, et al. Kinetic modeling of hyperpolarized 13C1-pyruvate metabolism in normal rats and TRAMP mice. J Magn Reson. 2010;202:85–92.CrossRefPubMed
84.
Hu S, et al. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab. 2011;14:131–42.CrossRefPubMed
85.
Park, J.M., et al. Fast 3D spiral chemical shift imaging of mitochondrial metabolism in brain with C6 glioma using hyperpolarized [2-13C]pyruvate, in Proceedings of the 21st Annual Scientific Meeting of the ISMRM. 2012: Salt Lake City, UT. p. Program #3938.
86.
Park, J.M., et al. Metabolic response of glioma to dichloroacetate measured in vivo by hyperpolarized 13C magnetic resonance spectroscopic imaging. Neuro Oncology. 2013.
87.
Nardo, G., et al. Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization. Cancer Res. 2011.
88.
Zulato, E., et al. Metabolic effects of anti-angiogenic therapy in tumor. Biochimie. 2012.
89.
Park JM, et al. Hyperpolarized 13C-lactate-to-bicarbonate ratio as a biomarker for monitoring acute response of anti-VEGF treatment. NMR Biomed. 2016;29(5):650–9.CrossRefPubMedPubMedCentral
90.
Park, J.M., et al. Measuring mitochondrial metabolism in rat brain in vivo using MR spectroscopy of hyperpolarized [2-13C]pyruvate. NMR Biomed. 2013.
91.
Gallagher FA, et al. 13C magnetic resonance spectroscopy measurements of glutaminase activity in human heptocellular carcinoma cells using hyperpolarized 13C-labeled glutamine. Magn Reson Med. 2008;60:253–7.CrossRefPubMed
Metadaten
Titel
A Metabolic Therapy for Malignant Glioma Requires a Clinical Measure
verfasst von
Zachary Corbin
Daniel Spielman
Lawrence Recht
Publikationsdatum
01.12.2017
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 12/2017
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-017-0637-y

Weitere Artikel der Ausgabe 12/2017

Current Oncology Reports 12/2017 Zur Ausgabe

Leukemia (A Aguayo, Section Editor)

Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia

Head and Neck Cancers (EY Hanna, Section Editor)

Reirradiation of Skull Base Tumors With Advanced Highly Conformal Techniques

Integrative Care (C Lammersfeld, Section Editor)

B Vitamin Complex and Chemotherapy-Induced Peripheral Neuropathy

Geriatric Oncology (AR MacKenzie, Section Editor)

Treatment of Glioblastoma in Older Adults

Gynecologic Cancers (NS Reed, Section Editor)

What’s New in Imaging for Gynecologic Cancer?

Sarcomas (SR Patel, Section Editor)

The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope

Neu im Fachgebiet Onkologie

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise